BWXT's sale of its medical business to Nordic Capital isn't a clean break. The company will retain a meaningful minority ownership stake in the divested business and continue providing specialized isotope and radiochemical expertise under the agreement. BWXT CEO Rex D. Geveden said the structure allows the company to remain a partner in the medical business's future growth while directing management resources toward nuclear national security and power markets. Since 2018, BWXT says it has expanded the product portfolio to include novel therapeutic isotopes.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.